180 Life Sciences Corp: Patent Approvals and Share Repurchase Initiatives
Patent Approval for Cognitive Aid Post-Operation
On May 1, 2025, 180 Life Sciences Corp, a biotech company specializing in novel drug development for inflammatory conditions, announced a significant milestone. The United States Patent and Trademark Office (USPTO) issued an official Notice of Allowance for U.S. Patent Application No. 17/556,584. This patent covers a novel method aimed at preventing or reducing post-operative cognitive dysfunction, marking a pivotal advancement for the company. This development is expected to bolster the company’s intellectual property portfolio and enhance its market position in the biotech sector.
Share Repurchase Initiatives
In a series of announcements made on April 30, 2025, 180 Life Sciences Corp declared its intention to repurchase shares, a move aimed at simplifying and strengthening its capital structure. The company entered into a Settlement and Mutual Release Agreement with Elray Resources, Inc. and Luxor Capital, LLC. As part of this agreement, 180 Life Sciences Corp will repurchase 1.32 million shares from Elray for $1 million. This strategic move is designed to consolidate ownership and improve the company’s financial standing.
Market and Financial Overview
As of April 29, 2025, 180 Life Sciences Corp’s stock was trading at $0.89 on the Nasdaq, with a market capitalization of $3.33 million. The company’s 52-week trading range has seen a high of $17.75 on October 15, 2024, and a low of $0.658 on April 8, 2025. The price-to-earnings ratio stands at -0.063856, reflecting the company’s current financial performance and market valuation.
Company Background
Founded in 2017, 180 Life Sciences Corp operates globally, focusing on the development of innovative biotechnological solutions. The company’s primary exchange is the Nasdaq, and it trades under the ticker symbol ATNF. For more information, interested parties can visit the company’s website at www.180lifesciences.com .
These recent developments highlight 180 Life Sciences Corp’s strategic efforts to enhance its market position through intellectual property advancements and capital structure optimization.